Farmácia/Notícias da Indústria
OMS pede transparência da indústria farmacêutica no relato dos dados de estudos clínicos.
10 Mai, 2021 | 10:40hWHO Calls For Pharma Transparency In Clinical Trial Data Reporting – Health Policy Watch
Diretriz WHO: Joint Statement on transparency and data integrity International Coalition of Medicines Regulatory Authorities (ICMRA) and WHO
Comentário no Twitter
Wide and open access to clinical data for new medicines and vaccines will help build trust and the expand access @WHO @US_FDA @EMA_News @CDSCO_INDIA_INF @MoHFW_INDIA @ICMRDELHI @JeremyFarrar @Chikwe_I @jarottingen @pahowho https://t.co/1OACILbdh6
— Soumya Swaminathan (@doctorsoumya) May 7, 2021
Estudo de coorte: Eventos arteriais, tromboembolismo venoso, trombocitopenia e sangramento após vacinação com Oxford-AstraZeneca ChAdOx1-S: 11 eventos tromboembólicos venosos em excesso por 100.000 vacinações; 2,5 tromboses venosas cerebrais em excesso por 100.000 vacinações.
7 Mai, 2021 | 10:48hEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Comentários: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion E Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion E Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Comentário no Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
Opinião | Covid-19: vacina Sputnik decola, graças ao impulso da revista Lancet.
7 Mai, 2021 | 10:46hCovid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ
Comentário no Twitter
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator @DoctorChrisVT unpicks the story of the Sputnik V vaccine https://t.co/lYf7l0lXcy
— The BMJ (@bmj_latest) May 6, 2021
Estudo randomizado: Monitoramento de tratamento farmacológico durante a indução de infliximabe não melhora a remissão da doença em pacientes com doenças inflamatórias crônicas imunomediadas.
7 Mai, 2021 | 10:42hEffect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (gratuito por tempo limitado)
Comentário: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Comentário no Twitter
Study findings do not support routine use of proactive therapeutic drug monitoring during infliximab induction for improving immune-mediated inflammatory disease remission rates https://t.co/sDslkVm3u9
— JAMA (@JAMA_current) May 5, 2021
Estudo randomizado: Entre pacientes com artrite reumatoide em remissão, a redução de DMARDs convencionais à metade da dose resultou em recorrência da doença em 25% dos pacientes, em comparação a 6% entre pacientes do grupo que manteve a dose padrão.
7 Mai, 2021 | 10:39hEffect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (gratuito por tempo limitado)
Comentário: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Breve revisão: Diagnóstico e tratamento do prolongamento do intervalo QT em pacientes com câncer.
7 Mai, 2021 | 10:19hHow to Diagnose and Manage QT Prolongation in Cancer Patients – JACC: CardioOncology
Comentário no Twitter (fio – clique para saber mais)
1/3 #JACCCardioOnc Just out 🔥 in @JACCJournals , our perspective on Management of QT prolongation in patients with cancer 👉🏼 https://t.co/s2Fo6lSIFc pic.twitter.com/FamiE0huCh
— Juan Lopez-Mattei (@onco_cardiology) March 16, 2021
Em ação surpreendente, EUA se posiciona a favor da liberação de patentes das vacinas contra COVID. “A administração Biden atrai aplausos dos pesquisadores em saúde pública e irrita a indústria farmacêutica.”
6 Mai, 2021 | 07:49hIn shock move, US backs waiving patents on COVID vaccines – Nature
Ver também: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT E Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for COVID-19 vaccines – UNAIDS E WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines – World Health Organization
Comentário no Twitter
These extraordinary times and circumstances of call for extraordinary measures.
The US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and we’ll actively participate in @WTO negotiations to make that happen. pic.twitter.com/96ERlboZS8
— Ambassador Katherine Tai (@AmbassadorTai) May 5, 2021
Estudo randomizado: Vacina Novavax é 49,4% eficaz contra a variante B.1.351 do SARS-CoV-2.
6 Mai, 2021 | 07:46hEstudo observacional no Catar: Vacina da Pfizer–BioNTech se mostrou 89,5% eficaz contra a variante B.1.1.7 e 75% eficaz contra a variante B.1.351. A eficácia da vacina contra doença grave, crítica ou fatal com qualquer variante do SARS-CoV-2 foi de 97,4%.
6 Mai, 2021 | 07:45h
Comentário no Twitter
📍GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy of 89.5% vs #B117 🇬🇧 variant & 75% vs #B1351 🇿🇦 variant for infection—but only with 2 doses. The 1 dose efficacy was just ~29% vs #B117 & ~17% vs #B1351. 🧵https://t.co/SprUfggnmh pic.twitter.com/VDWHiLsQLL
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
Estudo observacional em Israel: vacina da Pfizer-BioNTech é 95,3% eficaz contra a infecção por SARS-CoV-2.
6 Mai, 2021 | 07:43hComentários: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre E Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds – The BMJ